Drug Channels

SEPTEMBER 13, 2022

Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Biosimilars 75

Biosimilars Pharmacy Hospitals Marketing 75

DrugBank

SEPTEMBER 26, 2024

Biosimilars  Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.

Biosimilars 74

Biosimilars Clinical Trials Production FDA 74

Drug Channels

MARCH 14, 2023

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Analyzes Impact of Inflation Reduction Act on U.S. d/b/a Drug Channels Institute.

Pharmacy 87

Pharmacy Drugs Marketing Biosimilars 87

Drug Channels

FEBRUARY 22, 2022

On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drug pricing, reimbursement, and dispensing system. This 2022 edition addresses COVID-19 and its ongoing impact on the pharmacy and PBM industries. d/b/a Drug Channels Institute.

Pharmacy 72

Pharmacy Specialty Pharmacies Biosimilars Licensing 72

Drug Channels

OCTOBER 31, 2023

It's time for a super-sized Halloween roundup of wicked Drug Channels ’ tales. CVS Health frightens all but one Humira biosimilar maker away from its formulary. The gross-to-net bubble for anti-obesity GLP-1 drugs walks among us. Mark Cuban Cost Plus Drug Company conjures a partnership with Alto Pharmacy.

Biosimilars 80

Biosimilars Pharmacy Drugs 80

Drug Channels

DECEMBER 11, 2023

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2024 live video webinar. CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 69

Biosimilars Pharmacy Production Marketing 69

Drug Channels

JULY 11, 2022

Informa Connect's Hub and Specialty Pharmacy Models West. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Drug Channels readers will save 10% off the current registration rate when they use code 22DC10 *. Drug Channels, or any of its employees.

Specialty Pharmacies 83

Specialty Pharmacies Pharmacy Biosimilars Compliance 83

Drug Channels

FEBRUARY 21, 2023

On March 14, 2023, Drug Channels Institute will release The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drug pricing, reimbursement, and dispensing system. we highlight potential implications of the IRA for the drug channel. d/b/a Drug Channels Institute. In Subsection 12.5.1.,

Pharmacy 76

Pharmacy Specialty Pharmacies Licensing Licensing 76

Drug Channels

NOVEMBER 4, 2024

Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. What would happen if we disinfected the entire channel? All rights reserved.

Biosimilars 80

Biosimilars Hospitals Pharmacy Production 80

Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars 62

Biosimilars Pharmacy Drugs Marketing 62

Drug Channels

MARCH 30, 2023

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version.

Biosimilars 67

Biosimilars Pharmacy Drugs Production 67

Drug Channels

AUGUST 23, 2022

Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Drug Channels coastline: Howard Dean attacks patient-unfriendly cost shifting Cancer patients’ views of copay assistance My $0.02 d/b/a Drug Channels Institute.

Biosimilars 59

Biosimilars Specialty Pharmacies Pharmacy Drugs 59

Drug Channels

APRIL 29, 2024

April is over, so it's time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans—but maybe not for patients? Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Specialty Pharmacies 63

Specialty Pharmacies Pharmacy Biosimilars Drugs 63

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 85

Pharmacy Biosimilars Drugs Marketing 85

Drug Channels

OCTOBER 27, 2021

So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! It’s the biosimilar boom! d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 58

Biosimilars Hospitals Independent Pharmacies Pharmacy 58

Drug Channels

JANUARY 19, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 95

Biosimilars Pharmacy Drugs Production 95

FDA Law Blog: Biosimilars

DECEMBER 4, 2023

Houck — Separate decisions by federal district courts in Texas and Puerto Rico in the past two months provide cautionary tales for every pharmacy and wholesale distributor dispensing or distributing controlled substances. This post examines the Zarzamora pharmacy and prescribing red flags decision. d/b/a CVS/Pharmacy, Nos.

Pharmacy 139

Pharmacy Government Treatment Compliance 139

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. d/b/a Drug Channels Institute. to 1:30 p.m.

Biosimilars 63

Biosimilars Pharmacy Drugs 63

Drug Channels

APRIL 3, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The 2024 formularies described below should boost biosimilar adoption. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars 52

Biosimilars Pharmacy Drugs Production 52

Drug Channels

NOVEMBER 23, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. d/b/a Drug Channels Institute.

Specialty Pharmacies 64

Specialty Pharmacies Pharmacy Biosimilars Drugs 64

Drug Channels

MAY 30, 2023

d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Summer unofficially began over the weekend. to 1:30 p.m. Click here to learn more and sign up. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.

Biosimilars 61

Biosimilars Hospitals Pharmacy Drugs 61

The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Biosimilars marketed in the U.S. for the treatment of diabetes.

Biosimilars 52

Biosimilars Production FDA Approval FDA 52

Drug Channels

JUNE 27, 2021

As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing.

Biosimilars 52

Biosimilars Hospitals Pharmacy Vaccine 52

Drug Channels

AUGUST 25, 2021

Time to pack away the bathing suit and get serious again—with these curated curiosities combed from the now-barren Drug Channels beach: OptumRx joins the PBM GPO game Pharmacy DIR fees hit $11 billion A terrific resource on state biosimilar laws Patient views on utilization management Plus, my social media success…from a (print) newspaper ad!

Biosimilars 43

Biosimilars Pharmacy Drugs Research 43

Drug Channels

MAY 27, 2020

Before you venture outside for your lockdown barbeque, check out these noteworthy items off the Drug Channels grill: Payers predict how COVID-19 will affect formularies Our analysis of the 2020 retail-to-mail shift AmerisourceBergen profiles biosimilars Plus, CVS pharmacy offers a clever way to measure appropriate social distancing.

Biosimilars 52

Biosimilars Specialty Pharmacies Pharmacy Hospitals 52

Drug Channels

NOVEMBER 9, 2022

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2023. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. d/b/a Drug Channels Institute. to 1:30 p.m.

Specialty Pharmacies 80

Specialty Pharmacies Pharmacy Biosimilars Drugs 80

Drug Channels

NOVEMBER 23, 2021

Please join me for my upcoming live video webinar, Drug Channels Outlook 2022 , on December 17, 2021, from 12:00 p.m. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Happy Thanksgiving, everyone! to 1:30 p.m. Will you be there, too?

Specialty Pharmacies 61

Specialty Pharmacies Pharmacy Biosimilars Drugs 61

Drug Channels

APRIL 20, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 85

Biosimilars Pharmacy Drugs Production 85

Drug Channels

APRIL 25, 2023

While we wait for the Phillies turnaround, let’s oil up our gloves, lace up our cleats, and run the bases around this month's biggest hits: Foul ball : OptumRx prefers higher prices for the first Humira biosimilar Strikeout : Copay accumulators hurt health equity Bench warmer : Surprise? d/b/a Drug Channels Institute.

Biosimilars 67

Biosimilars Drugs Pharmacy 67

FDA Law Blog: Biosimilars

MARCH 24, 2024

By Faraz Siddiqui — As drug manufacturers battle the Health Resources and Services Administration (“HRSA”) in federal courts over the role of 340B contract pharmacies, an Eighth Circuit decision to uphold a 2021 Arkansas law may render those cases inconsequential in that state. Code Ann. § 23-92-604(c)(1), (2) (Act 1103).

Pharmacy 59

Pharmacy Regulations Compliance Drugs 59

Drug Channels

NOVEMBER 22, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. d/b/a Drug Channels Institute.

Specialty Pharmacies 61

Specialty Pharmacies Pharmacy FDA Biosimilars 61

FDA Law Blog: Biosimilars

MAY 30, 2024

Kirschenbaum — Last week, the United States Court of Appeals for the District of Columbia ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceutical manufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program. In United Therapeutics Corporation v.

Pharmacy 59

Pharmacy Pharmaceuticals Drugs Government 59

Drug Channels

NOVEMBER 24, 2020

In this issue: Rebate rule redux Most Favored Nation and healthcare benchmarking Amazon’s pharmacy customer opportunity Drug spending realities updated GPO consolidation Plus, I congratulate Dirk Rodgers of RxTrace on his retirement. d/b/a Drug Channels Institute. You can also join my more than 13,500 followers on LinkedIn.

Pharmacy 52

Pharmacy Specialty Pharmacies Biosimilars Doctors 52

Drug Channels

OCTOBER 25, 2022

Time for my Halloween roundup of wicked Drug Channels’ tales. Sink your fangs into Amgen’s fantastic new report on the biosimilar boom Wicked! d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This month’s tricks and treats: Eerie!

Biosimilars 64

Biosimilars Drugs Pharmacy 64

Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.

Pharmacy 77

Pharmacy Biosimilars Drugs Marketing 77

Drug Channels

JUNE 24, 2020

Before you declare your (socially-distanced) independence, get up close and personal with these Drug Channels fireworks: CVS launches a new GPO for its PBM CMS rethinks copay accumulators Here’s how GoodRx makes money Supermarkets face pharmacy challenges Plus, powerful and important comments from Ken Frazier, CEO of Merck.

Pharmacy 52

Pharmacy Biosimilars Drugs Marketing 52

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Click here to learn about MMIT’s Contract Validation solution.

Biosimilars 77

Biosimilars Pharmacy Therapies Production 77